Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 2/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38002 | 0.91 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Methyl Alcohol SCHEMBL27709287 | 0.89 | ATM (0.41) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL176982 | 0.89 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Formaldehyde SCHEMBL2941056 | 0.87 | ALDH1A1 (0.40) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Alcohol SCHEMBL27523839 | 0.85 | ALDH1A1 (0.40) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Acetonitrile SCHEMBL1262524 | 0.85 | ALDH1A1 (0.36) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Acetic Acid SCHEMBL8462148 | 0.85 | ATM (0.41) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL27824259 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| Sulfuric Acid SCHEMBL8936551 | 0.83 | MEN1 (0.38) | ALDH1A1MEN1KMT2ASMN1; SMN2TLR9 | |
| Thiourea SCHEMBL8854711 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311811-A1 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4- METHYLPYRAZOLE | Horizon Orphan LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180098964-A1 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLE | HORIZON ORPHAN LLC (US) | 2018-04-12 | — | — | US | disclosed |
| CN-106943398-A | The Serotype-dependent method of human individual is treated using 4 methylpyrazoles | 雷普特医疗公司 | 2017-07-14 | — | — | CN | disclosed |
| US-20170007578-A1 | Genotype Specific Methods for Treating Human Subjects Using 4-Methylpyrazole | HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA RAPTOR PHARMACEUTICALS INC.) | 2017-01-12 | — | — | US | disclosed |
| US-20160243082-A1 | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance | HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA RAPTOR PHARMACEUTICALS INC.) | 2016-08-25 | — | — | US | disclosed |
| CN-105769860-A | Application of clomethiazole as medicine for preventing and treating liver and esophageal disease | 乔海灵 | 2016-07-20 | — | — | CN | disclosed |
| CN-105664181-A | Application of chlorzoxazone serving as probe drug in determination of metabolic activity of human body to nitrosamine compounds | 乔海灵 | 2016-06-15 | — | — | CN | disclosed |
| US-9326971-B2 | 4-methylpyrazole formulations for inhibiting ethanol intolerance | RAPTOR PHARMACEUTICALS INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140155450-A1 | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance | RAPTOR PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130150419-A1 | 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCE | Raptor Therapeutiacs Inc. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120322843-A1 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLE | RAPTOR THERAPEUTICS INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120252857-A1 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4-METHYLPYRAZOLE | HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA RAPTOR PHARMACEUTICALS INC.) | 2012-10-04 | — | — | US | disclosed |
| CN-102458121-A | Genotype specific methods of treating human subjects using 4-methylpyrazole | RAPTOR THERAPEUTICS INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2440049-A1 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4- METHYLPYRAZOLE | Raptor Therapeutics Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110053999-A1 | 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCE | HORIZON ORPHAN LLC | 2011-03-03 | — | — | US | disclosed |
| WO-2010144518-A1 | GENOTYPE SPECIFIC METHODS FOR TREATING HUMAN SUBJECTS USING 4- METHYLPYRAZOLE | RAPTOR THERAPEUTICS INC. (US) | 2010-12-16 | — | — | WO | disclosed |